Literature DB >> 18256400

Pharmacogenomic biomarkers for prediction of severe adverse drug reactions.

Magnus Ingelman-Sundberg.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18256400     DOI： 10.1056/NEJMe0708842

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  24 in total

1.  Pharmacogenetics of nucleoside reverse-transcriptase inhibitor-associated peripheral neuropathy.

Authors:  Asha R Kallianpur; Todd Hulgan
Journal:  Pharmacogenomics       Date:  2009-04       Impact factor: 2.533

2.  Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus.

Authors:  Gokhan Okan; Serpil Yaylaci; Onder Peker; Sabahattin Kaymakoglu; Murat Saruc
Journal:  World J Gastroenterol       Date:  2008-08-07       Impact factor: 5.742

3.  The future costs, risks and rewards of drug development: the economics of pharmacogenomics.

Authors:  Joseph Cook; Graeme Hunter; John A Vernon
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 4.  Current progress in pharmacogenetics.

Authors:  John D Blakey; Ian P Hall
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

5.  Determining molecular predictors of adverse drug reactions with causality analysis based on structure learning.

Authors:  Mei Liu; Ruichu Cai; Yong Hu; Michael E Matheny; Jingchun Sun; Jun Hu; Hua Xu
Journal:  J Am Med Inform Assoc       Date:  2013-12-11       Impact factor: 4.497

Review 6.  Pharmacogenomics in the clinic.

Authors:  Mary V Relling; William E Evans
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

7.  DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism.

Authors:  Venkatrao Vantaku; Chandra Sekhar Amara; Danthasinghe Waduge Badrajee Piyarathna; Sri Ramya Donepudi; Chandrashekar R Ambati; Vasanta Putluri; Wei Tang; Kimal Rajapakshe; Marcos Roberto Estecio; Martha K Terris; Patricia D Castro; Michael M Ittmann; Stephen B Williams; Seth P Lerner; Arun Sreekumar; Roni Bollag; Cristian Coarfa; Michael D Kornberg; Yair Lotan; Stefan Ambs; Nagireddy Putluri
Journal:  Carcinogenesis       Date:  2019-11-25       Impact factor: 4.944

Review 8.  Expectations, validity, and reality in pharmacogenetics.

Authors:  Nita A Limdi; David L Veenstra
Journal:  J Clin Epidemiol       Date:  2009-12-07       Impact factor: 6.437

9.  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.

Authors:  Naga Chalasani; Robert J Fontana; Herbert L Bonkovsky; Paul B Watkins; Timothy Davern; Jose Serrano; Hongqiu Yang; James Rochon
Journal:  Gastroenterology       Date:  2008-09-17       Impact factor: 22.682

Review 10.  Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.

Authors:  Stefan Vegter; Cornelis Boersma; Mark Rozenbaum; Bob Wilffert; Gerjan Navis; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.